NCT00477269View on ClinicalTrials.gov

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Imatinib mesylate

DRUG

Placebo

Trial Locations (13)

10032

Novartis Investigative Site, New York

30625

Novartis Investigative Site, Hanover

35385

Novartis Investigative Site, Giessen

90073

Novartis Investigative Site, Los Angeles

07112

Novartis investigative site, Newark

A-8036

Novartis Investigative Site, Graz

Unknown

Novartis Investigative site, Graz

Novartis Investigative site, Giessen

Novartis Investigative site, Hanover

Novartis Investigative site, Glasgow

Novartis Investigative site, Papworth Everard

CB23 3RE

Novartis Investigative Site, Cambridge

G11 6NT

Novartis Investigative Site, Glasgow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY